仿制药一致性评价国内外研究进展

• 管理研究 • 上一篇

仿制药一致性评价国内外研究进展

马志爽,李勇

中国药科大学国际医药商学院,中国药科大学国际医药商学院

收稿日期:2018-06-12 修回日期:2018-06-12 出版日期:2018-08-25 发布日期:2018-08-25
基金资助:
江苏省高校哲学社会科学指导项目基金(基金编号：2017SJB0052) ；中国药科大学国际医药商学院力凡胶囊科研基金(基金编号：LFJJ-07)

Research Progress of Generic Drug Conformance Assessment at Home and Abroad

School of International Pharmaceutical Business of China Pharmaceutical University,

Received:2018-06-12 Revised:2018-06-12 Online:2018-08-25 Published:2018-08-25

摘要/Abstract

摘要： 在我国药品市场中仿制药占据绝大部分市场份额，然而仿制药的质量参差不齐，严重影响了广大患者的用药安全，因此，如何提升仿制药的质量在政府、学术界以及整个医药行业中一直备受关注。本文整理了国内外学者们针对仿制药一致性评价问题的研究，从我国仿制药的发展现状，仿制药一致性评价原则与方法，仿制药一致性评价对医药行业的影响，完善仿制药一致性评价体系的对策等角度细致展开，以期为开展仿制药一致性评价研究提供参考.

Abstract: Generic drugs account for most of the market share in the pharmaceutical market in China. However， the quality of generic drugs is uneven， which seriously affects the safety of medication for the majority of patients. Therefore， how to improve the quality of generic drugs has attracted much attention in government， academia and the entire pharmaceutical industry. This article collates domestic and foreign scholars′ researches on the issue of generic drug conformity assessment. From the development status of China′s generic drugs， principles and methods for consistency assessment of generic drugs， the impact of the conformity assessment of generic drugs on the pharmaceutical industry， and the measures to improve the conformity assessment system for generic drugs， four perspectives were developed. In order to provide reference for carrying out generic pharmaceutical consistency evaluation research.

马志爽,李勇. 仿制药一致性评价国内外研究进展[J]. .

参考文献

[1]王静,韩晓亮,孟锐.探寻我国仿制药的发展策略[J].中国药事,2011,25(5):427-429.
[2]许明哲,牛剑钊,陈华,等.浅谈仿制药质量一致性评价过程管理的原则及政策依托[J].中国新药杂志,2013,22(21):2475-2478.
[3]余珊珊,张正付,李正奇.仿制药一致性评价现状调查及对策[J].中国临床药理学与治疗学,2015,20(1):118-120+100.
[4]牛剑钊,林兰,马锐,等.我国仿制药研究及监管现状[J].中国新药杂志,2014, 23(1):6-10.
[5]霍秀敏.从注册角度谈如何提高化学仿制药的质量[J].中国执业药师,2008,5(09):36-37.
[6]韩静,张丹,刘会臣.仿制药的生物不等效风险与质量一致性评价[J].中国新药杂志,2014, 23(24):2897-2901.
[7]谭德讲,冯国双,朱容蝶,等.一致性评价所用统计分析方法辨析[J].中国新药杂志,2017, 26(24):2881-2886.
[8]黄海伟,牛剑钊,林兰,等.美日参比制剂目录的介绍与我国参比制剂目录遴选原则的探讨[J].药物分析杂志,2013,33(11):2009-2012.
[9]朱凤昌,王爱国,韩凤,等.口服固体仿制药品生物等效性研究国际指导原则要点调研[J].中国药学杂志,2016,51(20):1807-1814.
[10]冯毅,朱波.关于我国仿制药质量一致性评价的研究及建议[J].中国新药杂志,2016,25 (1):19-26+41.
[11]李勇,赵梦蕊,马爱霞,等.我国仿制药一致性评价对药品短缺的影响分析[J].卫生经济研究,2017(5):47-50.
[12]胡林峰,虞忠.仿制药一致性评价的产业影响研究[J].中国医药工业杂志,2016,47(8): 1097-1101.
[13]丁锦希,刘莹芳,姚雪芳,等. 一致性评价对药品集中采购竞价分组的影响机制分析[J]. 中国医药工业杂志, 2017, 48(4): 605-613.
[14]李岩.关于完善我国仿制药品注册管理体制的研究[D].辽宁:沈阳药科大学, 2009:1-65
[15]苏涛,常峰,邵蓉.药品质量的规制分析[J].中国药事, 2010,24(5):431-434
[16]郁庆华,谢冉行.开展仿制药质量一致性评价的探讨[J].上海医药,2014,35(07):49-53.
[17]黄宝斌,Christina Forge-Wimme.我国化学仿制药生产企业申请达到WHO药品预认证标准的激励因素和技术差距研究[J].中国新药杂志,2015,24(7):725-729
[18]武小赟,邓婷,宋丹.市场导向下的药企间仿制药一致性评价横向合作的现状分析及对策[J]. 中国实验方剂学杂志, 2017, 23(19): 202-206.
[19]郑洁,陈玉文.日本药品品质再评价工程对我国仿制药一致性评价的借鉴[J].中国药业, 2014,23(18):6-7.
[20]林兰,牛剑钊,许明哲,等.国外仿制药一致性评价比较分析[J].中国新药杂志,2013,22(21): 2470-2474.
[21] Meredith P. Bioequivalence and other unresolved issues in generic drug substitution[J].Clin Ther, 2003,25(11):2875-2890．
[22] Johnston Gordon. Generic biopharmaceuticals: Towards a science-based abbreviated process [J]. Journal of Generic Medicines,2005,118-124.
[23] Takagi Toshihide, Ramachandran Chandrasekharan, Bermejo Marival, Yamashita Shinji, Yu Lawrence X, Amidon Gordon L. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.[J]. Molecular Pharmaceutics, 2006,36:.
[24] Amidon K S, Langguth P, Lennern?s H, Yu L, Amidon G L. Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy.[J]. Clinical Pharmacology and Therapeutics,2011,903:.
[25] G. Dranitsaris, K. Dorward, E. Hatzimichael, E. Amir. Clinical trial design in biosimilar drug development[J]. Investigational New Drugs,2013,312:.
[26]Kaur Paramjeet, Chaurasia Chandra S., Davit Barbara M., Dale P. Conner. Bioequivalence Study Designs for Generic Solid Oral Anticancer Drug Products: Scientific and Regulatory Considerations. [J]. The Journal of Clinical Pharmacology2003,1252-1260
[27] Wang Rong, Conner Dale P., Li Bing V. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products[J]. The AAPS Journal, 2016, 10:.
[28]宋春黎,牛剑钊,张启明,等.日本药品再评价制度介绍[J].中国药学杂志,2014,49(12):1087- 1090.